Enantiomerically pure phosphoindoles as HIV inhibitors
US7960428B2 · kind B2 · utility
1Cited by
23References
42Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 28, 2007 |
| Grant date | Jun 14, 2011 |
| Priority date | — |
| Expiry date | Jul 11, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.